Trade Lisata Therapeutics, Inc - LSTA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.15 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.79 |
| Open | 2.57 |
| 1-Year Change | -18.41% |
| Day's Range | 2.54 - 2.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 2, 2024 | 2.79 | 0.20 | 7.72% | 2.59 | 2.79 | 2.53 |
| May 1, 2024 | 2.79 | 0.22 | 8.56% | 2.57 | 2.79 | 2.57 |
| Apr 30, 2024 | 2.69 | 0.06 | 2.28% | 2.63 | 2.72 | 2.60 |
| Apr 29, 2024 | 2.66 | 0.16 | 6.40% | 2.50 | 2.66 | 2.50 |
| Apr 26, 2024 | 2.69 | 0.08 | 3.07% | 2.61 | 2.75 | 2.55 |
| Apr 25, 2024 | 2.64 | -0.10 | -3.65% | 2.74 | 2.74 | 2.59 |
| Apr 24, 2024 | 2.75 | 0.25 | 10.00% | 2.50 | 2.77 | 2.50 |
| Apr 23, 2024 | 2.64 | 0.14 | 5.60% | 2.50 | 2.84 | 2.50 |
| Apr 22, 2024 | 2.64 | -0.05 | -1.86% | 2.69 | 2.69 | 2.50 |
| Apr 19, 2024 | 2.64 | -0.02 | -0.75% | 2.66 | 2.79 | 2.59 |
| Apr 18, 2024 | 2.64 | 0.06 | 2.33% | 2.58 | 2.73 | 2.58 |
| Apr 17, 2024 | 2.69 | -0.13 | -4.61% | 2.82 | 2.82 | 2.61 |
| Apr 16, 2024 | 2.78 | -0.04 | -1.42% | 2.82 | 2.82 | 2.67 |
| Apr 15, 2024 | 2.82 | -0.04 | -1.40% | 2.86 | 2.87 | 2.82 |
| Apr 12, 2024 | 2.86 | -0.13 | -4.35% | 2.99 | 2.99 | 2.82 |
| Apr 11, 2024 | 2.97 | 0.15 | 5.32% | 2.82 | 3.06 | 2.82 |
| Apr 10, 2024 | 2.89 | -0.03 | -1.03% | 2.92 | 2.95 | 2.82 |
| Apr 9, 2024 | 3.01 | 0.15 | 5.24% | 2.86 | 3.01 | 2.82 |
| Apr 8, 2024 | 2.86 | 0.04 | 1.42% | 2.82 | 2.86 | 2.82 |
| Apr 5, 2024 | 2.87 | -0.08 | -2.71% | 2.95 | 3.06 | 2.82 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lisata Therapeutics, Inc Company profile
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).
Financial summary
BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).
Equity composition
Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.
| Industry: | Biotechnology & Medical Research (NEC) |
110 Allen Road
Second Floor
07920
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com